Your NEJM Group Today: E-Cigarette Clinical Pearls, PPIs & Fundic Gland Polyps, Colorado Urgent Care Opportunity (FREE)
By the Editors
NEJM Group offers so many valuable resources for practicing clinicians. Here ' s what we chose for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 6, 2016 Category: Primary Care Source Type: news
PPI Use and Risk of Hepatic Encephalopathy in Cirrhotic Patients PPI Use and Risk of Hepatic Encephalopathy in Cirrhotic Patients
Patients with cirrhosis who are treated with a proton pump inhibitor (PPI) face an increased risk of hepatic encephalopathy, and the risk rises in a dose-dependent fashion, a large study from Taiwan has found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 23, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Two Weeks of PAM Triple Therapy for H pylori as Effective as PACTwo Weeks of PAM Triple Therapy for H pylori as Effective as PAC
Triple therapy combining a proton-pump inhibitor (PPI), amoxicillin, and high-dose metronidazole (PAM) given thrice daily for 14 days provides Helicobacter pylori eradication rates similar to those with triple-therapy regimens containing clarithromycin (PAC), according to a new report. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 19, 2016 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
EndoGastric Solutions wins nod from medical society for Esophyx anti-GERD device
The American Gastroenterological Assn. recommended that insurers cover the Esophyx device for treating gastroesophageal reflux disease made by EndoGastric Solutions.
Citing the data from a quartet of randomized, controlled trials, the AGA said transoral incisionless fundiplication with Esophyx ought to be reimbursed for the 20% to 40% of GERD patients who don’t respond to medication.
“[T]he 3‐year-plus evidence is sufficient to demonstrate sustainable improvement in health outcomes, symptom relief, decrease in [proton pump inhibitor] utilization and improvement in esophageal pH with transoral fundoplicati...
Source: Mass Device - June 17, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Blog American Gastroenterological Assn. (AGA) EndoGastric Solutions Source Type: news
PPI Side Effects Destroying Your Blood Vessels
It seems whenever I turn on my TV these days, there’s Larry the Cable Guy with a quick fix for heartburn.
He makes it sound so simple. Just pop a pill, eat all the chili dogs you want, and no more heartburn… at least for a couple of weeks.
What Is Heartburn?
Heartburn is an irritation of the esophagus that is caused by stomach acid. It has nothing to do with the heart.
But a new study has found a link between proton-pump inhibitors (PPIs) — heartburn drugs — and the premature aging of blood vessels.
Heartburn Drugs PPI Side Effects
Researchers focused on the effects of two PPIs, one of which is Nexium. They...
Source: Al Sears, MD Natural Remedies - June 16, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Heart Health Source Type: news
Proton pump inhibitor use increases risk of osteoporosis
Published in the International Journal of Rheumatic Diseases, researchers from Iran found that PPI use is associated with an increased risk of developing osteoporosis.
Endocrinology Advisor (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 10, 2016 Category: Endocrinology Source Type: news
Disappointing results for GI bleed prevention in high-risk aspirin users
SAN DIEGO – Neither a proton pump inhibitor nor an H2 antagonist is an optimal choice for users of low-dose aspirin with previously confirmed ulcer bleeding, according to data from a 12-month... (Source: Family Practice News)
Source: Family Practice News - June 1, 2016 Category: Primary Care Source Type: news
PPIs, Elimination Diet, and/or Budesonide for EoEPPIs, Elimination Diet, and/or Budesonide for EoE
Do patients with eosinophilic esophagitis sustain remission from disease with PPIs, an elimination diet, and/or budesonide? Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 27, 2016 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news
Inflammation, Not Acid, Cause of GERD, Study SuggestsInflammation, Not Acid, Cause of GERD, Study Suggests
A small study found that men with severe GERD who stopped PPIs developed signs of GERD within 2 weeks; biopsies suggested inflammation, not direct damage from acid, may be the underlying cause. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 17, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
EndoStim raises $25m Series D for neurostim GERD device
Five months after spiking its plans for an initial public offering, EndoStim said today that it raised a $25 million Series D round for the neurostimulation device it’s developing to treat gastroesophageal reflux disease.
Saint Louis- and Nijmegen, Holland-based EndoStim said Endeavour Vision led the round, joined by existing backer Santé Ventures and new investors Wellington Partners and Gimv.
Endostim said it plans to use the proceeds to expand its sales footprint in Europe and to fund a randomized, sham-controlled U.S. trial.
The company describes its system in form and function to a pacemaker, with the dev...
Source: Mass Device - May 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation EndoStim Gastrointestinal Source Type: news
Proton Pump Inhibitors Accelerate Cellular AgingProton Pump Inhibitors Accelerate Cellular Aging
A new study suggests that chronic use of a proton pump inhibitor (PPI) accelerates aging of endothelial cells. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 12, 2016 Category: Gastroenterology Tags: Family Medicine/Primary Care News Source Type: news
3 Surprising Things That Increase Your Dementia Risk
SPECIAL FROM
“As many as five million Americans age 65 and older may have Alzheimer’s Disease, and that number is expected to double for every five-year interval beyond age 65.” — the National Institute of Neurologic Disorders and Stroke.
While Alzheimer’s is the most common form of dementia, it is not the only form.
Risk factors for all kinds of dementia include, age, alcohol use, smoking, atherosclerosis, diabetes, hypertension, and genetics. However, researchers have found some startling connections that show other surprising factors that can heighten your risk:
Risk Factor #1: Antic...
Source: Healthy Living - The Huffington Post - May 6, 2016 Category: Consumer Health News Source Type: news
Efficacy of PPIs in Patients With Esophageal EosinophiliaEfficacy of PPIs in Patients With Esophageal Eosinophilia
Do proton pump inhibitors induce clinicohistologic remission in patients with symptomatic esophageal eosinophilia? Clinical Gastroenterology and Hepatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 2, 2016 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news
Nearly one in four babies in NICUs receive acid suppressing medication
Though not approved for use in newborns, doctors prescribe the drugs to treat gastroesophageal reflux disease (GERD) and to help with other conditions diagnosed in neonatal intensive care units (NICUs). However, several published studies have associated the use of some acid suppression medications in hospitalized high-risk babies with infections, necrotizing enterocolitis and increased risk of death. From January 2006 through March 2013, 28,989 of 122,002 of babies, or 23.8 percent, received a histamine-2 receptor antagonist or proton pump inhibitor. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 27, 2016 Category: Science Source Type: news
Nearly 1 in 4 babies in NICUs receive acid suppressing medication
(Nationwide Children's Hospital) Though not approved for use in newborns, doctors prescribe the drugs to treat gastroesophageal reflux disease (GERD) and to help with other conditions diagnosed in neonatal intensive care units (NICUs). However, several published studies have associated the use of some acid suppression medications in hospitalized high-risk babies with infections, necrotizing enterocolitis and increased risk of death. From January 2006 through March 2013, 28,989 of 122,002 of babies, or 23.8 percent, received a histamine-2 receptor antagonist or proton pump inhibitor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2016 Category: Global & Universal Source Type: news
